FDA’s Pazdur: Accelerated Approval Is ‘Under Attack,' Supporters Can’t Afford To Remain Silent

 
• By Sarah Karlin-Smith
  
Reps. Diana DeGette, Fred Upton and Pazdur and Sharpless discuss Cures 2.0
Cures 2.0 Congressional sponsors discuss expedited approval pathways with FDA’s Pazdur and NCI’s Sharpless • Source: Friends of Cancer Research
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from United States

More from North America